0
ARTICLE |

Key Witness Against Morning Sickness Drug Faces Scientific Fraud Charges

Andrew Skolnick
JAMA. 1990;263(11):1468-1473. doi:10.1001/jama.1990.03440110020003.
Text Size: A A A
Published online

ABSTRACT

WILLIAM McBRIDE, MD, the Australian obstetrician many credit as being among the first to notice the association between thalidomide and birth defects (see accompanying article), is now facing charges of scientific fraud and professional misconduct before an Australian medical tribunal.

Some of the 15 charges against him concern his efforts to show that the anti-morning sickness drug Bendectin is also teratogenic. According to the New South Wales State Department of Health's Complaints Unit in Sydney, McBride is accused of fabricating data in a published study and falsely testifying in US federal courts about his research. His testimony played a key role in many of the lawsuits against Merrell Dow Pharmaceuticals, Inc, Cincinnati, Ohio, which manufactured Bendectin, the only drug approved by the US Food and Drug Administration for the treatment of nausea during pregnancy.

Responding to the onslaught of hundreds of lawsuits, Merrell Dow halted production of its anti-morning sickness

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs